Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

2.

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, Kwong PD.

J Virol. 2010 Mar;84(6):2955-62. doi: 10.1128/JVI.02257-09. Epub 2009 Dec 30.

3.

Role of HIV membrane in neutralization by two broadly neutralizing antibodies.

Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch S, Sun L, Harrison SC, Haynes BF, Chen B.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20234-9. doi: 10.1073/pnas.0908713106. Epub 2009 Nov 11.

4.

Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Xu H, Song L, Kim M, Holmes MA, Kraft Z, Sellhorn G, Reinherz EL, Stamatatos L, Strong RK.

J Virol. 2010 Jan;84(2):1076-88. doi: 10.1128/JVI.02113-09. Epub 2009 Nov 11.

5.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

6.

Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.

de la Arada I, Julien JP, de la Torre BG, Huarte N, Andreu D, Pai EF, Arrondo JL, Nieva JL.

J Phys Chem B. 2009 Oct 15;113(41):13626-37. doi: 10.1021/jp905965h.

PMID:
19754136
7.

Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.

Bryson S, Julien JP, Hynes RC, Pai EF.

J Virol. 2009 Nov;83(22):11862-75. doi: 10.1128/JVI.01604-09. Epub 2009 Sep 9.

8.

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Stamatatos L, Morris L, Burton DR, Mascola JR.

Nat Med. 2009 Aug;15(8):866-70. doi: 10.1038/nm.1949. Review.

PMID:
19525964
9.

Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Watson DS, Szoka FC Jr.

Vaccine. 2009 Jul 23;27(34):4672-83. doi: 10.1016/j.vaccine.2009.05.059. Epub 2009 Jun 9.

10.

Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.

Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, Reinherz EL, Wagner G, Kim M.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9057-62. doi: 10.1073/pnas.0901474106. Epub 2009 May 19.

11.

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC.

J Virol. 2009 Jul;83(14):7337-48. doi: 10.1128/JVI.00110-09. Epub 2009 May 13.

12.

Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library.

Walker LM, Bowley DR, Burton DR.

J Mol Biol. 2009 Jun 5;389(2):365-75. doi: 10.1016/j.jmb.2009.04.019. Epub 2009 Apr 16.

13.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC.

Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.

PMID:
19287373
14.

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, Phung P, Tian Y, Resnick DA, Ma X, Mariano TM, Petropoulos CJ, Taylor JW, Katinger H, Arnold E.

J Virol. 2009 May;83(10):5087-100. doi: 10.1128/JVI.00184-09. Epub 2009 Mar 11.

15.

Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1.

Matyas GR, Beck Z, Karasavvas N, Alving CR.

Biochim Biophys Acta. 2009 Mar;1788(3):660-5. doi: 10.1016/j.bbamem.2008.11.015. Epub 2008 Dec 3.

16.

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L.

J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5. Erratum in: J Virol. 2009 May;83(9):4713-5.

17.

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M.

J Virol. 2009 Jan;83(1):188-99. doi: 10.1128/JVI.01583-08. Epub 2008 Oct 15.

18.

Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.

Julien JP, Bryson S, Nieva JL, Pai EF.

J Mol Biol. 2008 Dec 12;384(2):377-92. doi: 10.1016/j.jmb.2008.09.024. Epub 2008 Sep 18.

PMID:
18824005
19.

Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Thomson CA, Bryson S, McLean GR, Creagh AL, Pai EF, Schrader JW.

EMBO J. 2008 Oct 8;27(19):2592-602. doi: 10.1038/emboj.2008.179. Epub 2008 Sep 4.

20.

The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Huarte N, Lorizate M, Maeso R, Kunert R, Arranz R, Valpuesta JM, Nieva JL.

J Virol. 2008 Sep;82(18):8986-96. doi: 10.1128/JVI.00846-08. Epub 2008 Jul 2.

Supplemental Content

Support Center